APO Research
Talk to an analyst

APO RESEARCH · REPORT

HPV Therapeutic Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HPV Therapeutic Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchHPV Therapeutic Vaccines Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal HPV Therapeutic Vaccines Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal HPV Therapeutic Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HPV Therapeutic Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal HPV Therapeutic Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global HPV Therapeutic Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HPV Therapeutic Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HPV Therapeutic Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HPV Therapeutic Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HPV Therapeutic Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HPV Therapeutic Vaccines market include Shanghai Bovax Biotechnology Co., Ltd., Sanofi Pasteur, Johnson and Johnson., Pfizer, GlaxoSmithKline plc, Wantai BioPharm, Serum Institute, Profectus BioSciences, Inc. and Merck & Co., Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global HPV Therapeutic Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HPV Therapeutic Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HPV Therapeutic Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global HPV Therapeutic Vaccines market.

HPV Therapeutic Vaccines Segment by Company

Shanghai Bovax Biotechnology Co., Ltd.

Sanofi Pasteur

Johnson and Johnson.

Pfizer

GlaxoSmithKline plc

Wantai BioPharm

Serum Institute

Profectus BioSciences, Inc.

Merck & Co., Inc

ISA Pharmaceuticals

INOVIO Pharmaceuticals

Emergent BioSolutions

Astellas Pharma

2A Pharma AB

HPV Therapeutic Vaccines Segment by Type

Bivalent HPV vaccine

Quadrivalent HPV vaccine

HPV Therapeutic Vaccines Segment by Application

Man

Woman

HPV Therapeutic Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global HPV Therapeutic Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the HPV Therapeutic Vaccines key companies, revenue, market share, and recent developments.

3. To split the HPV Therapeutic Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions HPV Therapeutic Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HPV Therapeutic Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze HPV Therapeutic Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HPV Therapeutic Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HPV Therapeutic Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HPV Therapeutic Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HPV Therapeutic Vaccines industry.

Chapter 3: Detailed analysis of HPV Therapeutic Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of HPV Therapeutic Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of HPV Therapeutic Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HPV Therapeutic Vaccines Industry Trends Table 2. HPV Therapeutic Vaccines Industry Drivers Table 3. HPV Therapeutic Vaccines Industry Opportunities and Challenges Table 4. HPV Therapeutic Vaccines Industry Restraints Table 5. Global HPV Therapeutic Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HPV Therapeutic Vaccines Revenue Share by Company (2021-2026) Table 7. Global HPV Therapeutic Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global HPV Therapeutic Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global HPV Therapeutic Vaccines Company, Product Type & Application Table 10. Global HPV Therapeutic Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global HPV Therapeutic Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bivalent HPV vaccine Table 15. Significant Companies of Quadrivalent HPV vaccine Table 16. Global HPV Therapeutic Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global HPV Therapeutic Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global HPV Therapeutic Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global HPV Therapeutic Vaccines Sales Value Share by Type (2021-2026) Table 20. Global HPV Therapeutic Vaccines Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Man Table 22. Significant Companies of Woman Table 23. Global HPV Therapeutic Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global HPV Therapeutic Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global HPV Therapeutic Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global HPV Therapeutic Vaccines Sales Value Share by Application (2021-2026) Table 27. Global HPV Therapeutic Vaccines Sales Value Share by Application (2027-2032) Table 28. Global HPV Therapeutic Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global HPV Therapeutic Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global HPV Therapeutic Vaccines Sales Value Share by Region (2021-2026) Table 31. Global HPV Therapeutic Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global HPV Therapeutic Vaccines Sales Value Share by Region (2027-2032) Table 33. Global HPV Therapeutic Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global HPV Therapeutic Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global HPV Therapeutic Vaccines Sales Value Market Share by Country (2021-2026) Table 36. Global HPV Therapeutic Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global HPV Therapeutic Vaccines Sales Value Market Share by Country (2027-2032) Table 38. Shanghai Bovax Biotechnology Co., Ltd. Company Information Table 39. Shanghai Bovax Biotechnology Co., Ltd. Business Overview Table 40. Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Product Portfolio Table 42. Shanghai Bovax Biotechnology Co., Ltd. Recent Development Table 43. Sanofi Pasteur Company Information Table 44. Sanofi Pasteur Business Overview Table 45. Sanofi Pasteur HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Sanofi Pasteur HPV Therapeutic Vaccines Product Portfolio Table 47. Sanofi Pasteur Recent Development Table 48. Johnson and Johnson. Company Information Table 49. Johnson and Johnson. Business Overview Table 50. Johnson and Johnson. HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Johnson and Johnson. HPV Therapeutic Vaccines Product Portfolio Table 52. Johnson and Johnson. Recent Development Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Pfizer HPV Therapeutic Vaccines Product Portfolio Table 57. Pfizer Recent Development Table 58. GlaxoSmithKline plc Company Information Table 59. GlaxoSmithKline plc Business Overview Table 60. GlaxoSmithKline plc HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline plc HPV Therapeutic Vaccines Product Portfolio Table 62. GlaxoSmithKline plc Recent Development Table 63. Wantai BioPharm Company Information Table 64. Wantai BioPharm Business Overview Table 65. Wantai BioPharm HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Wantai BioPharm HPV Therapeutic Vaccines Product Portfolio Table 67. Wantai BioPharm Recent Development Table 68. Serum Institute Company Information Table 69. Serum Institute Business Overview Table 70. Serum Institute HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Serum Institute HPV Therapeutic Vaccines Product Portfolio Table 72. Serum Institute Recent Development Table 73. Profectus BioSciences, Inc. Company Information Table 74. Profectus BioSciences, Inc. Business Overview Table 75. Profectus BioSciences, Inc. HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Profectus BioSciences, Inc. HPV Therapeutic Vaccines Product Portfolio Table 77. Profectus BioSciences, Inc. Recent Development Table 78. Merck & Co., Inc Company Information Table 79. Merck & Co., Inc Business Overview Table 80. Merck & Co., Inc HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck & Co., Inc HPV Therapeutic Vaccines Product Portfolio Table 82. Merck & Co., Inc Recent Development Table 83. ISA Pharmaceuticals Company Information Table 84. ISA Pharmaceuticals Business Overview Table 85. ISA Pharmaceuticals HPV Therapeutic Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. ISA Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio Table 87. ISA Pharmaceuticals Recent Development Table 88. INOVIO Pharmaceuticals Company Information Table 89. INOVIO Pharmaceuticals Business Overview Table 90. INOVIO Pharmaceuticals HPV Therapeutic Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. INOVIO Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio Table 92. INOVIO Pharmaceuticals Recent Development Table 93. Emergent BioSolutions Company Information Table 94. Emergent BioSolutions Business Overview Table 95. Emergent BioSolutions HPV Therapeutic Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Emergent BioSolutions HPV Therapeutic Vaccines Product Portfolio Table 97. Emergent BioSolutions Recent Development Table 98. Astellas Pharma Company Information Table 99. Astellas Pharma Business Overview Table 100. Astellas Pharma HPV Therapeutic Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Astellas Pharma HPV Therapeutic Vaccines Product Portfolio Table 102. Astellas Pharma Recent Development Table 103. 2A Pharma AB Company Information Table 104. 2A Pharma AB Business Overview Table 105. 2A Pharma AB HPV Therapeutic Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. 2A Pharma AB HPV Therapeutic Vaccines Product Portfolio Table 107. 2A Pharma AB Recent Development Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. HPV Therapeutic Vaccines Product Image Figure 2. Global HPV Therapeutic Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HPV Therapeutic Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global HPV Therapeutic Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bivalent HPV vaccine Image Figure 8. Quadrivalent HPV vaccine Image Figure 9. Global HPV Therapeutic Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global HPV Therapeutic Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global HPV Therapeutic Vaccines Sales Value Share by Type (2021-2032) Figure 12. Man Image Figure 13. Woman Image Figure 14. Global HPV Therapeutic Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global HPV Therapeutic Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global HPV Therapeutic Vaccines Sales Value Share by Application (2021-2032) Figure 17. Global HPV Therapeutic Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global HPV Therapeutic Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America HPV Therapeutic Vaccines Sales Value (2021-2032) & (US$ Million) Figure 20. North America HPV Therapeutic Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe HPV Therapeutic Vaccines Sales Value (2021-2032) & (US$ Million) Figure 22. Europe HPV Therapeutic Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific HPV Therapeutic Vaccines Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific HPV Therapeutic Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America HPV Therapeutic Vaccines Sales Value (2021-2032) & (US$ Million) Figure 26. South America HPV Therapeutic Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa HPV Therapeutic Vaccines Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa HPV Therapeutic Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Bivalent HPV vaccine
  • Quadrivalent HPV vaccine
Applications
  • Man
  • Woman
Companies covered
  • Shanghai Bovax Biotechnology Co., Ltd.
  • Sanofi Pasteur
  • Johnson and Johnson.
  • Pfizer
  • GlaxoSmithKline plc
  • Wantai BioPharm
  • Serum Institute
  • Profectus BioSciences, Inc.
  • Merck & Co., Inc
  • ISA Pharmaceuticals
  • INOVIO Pharmaceuticals
  • Emergent BioSolutions
  • Astellas Pharma
  • 2A Pharma AB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HPV Therapeutic Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HPV Therapeutic Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 HPV Therapeutic Vaccines Market Dynamics
  1. 2.1 HPV Therapeutic Vaccines Industry Trends
  2. 2.2 HPV Therapeutic Vaccines Industry Drivers
  3. 2.3 HPV Therapeutic Vaccines Industry Opportunities and Challenges
  4. 2.4 HPV Therapeutic Vaccines Industry Restraints
3 HPV Therapeutic Vaccines Market by Company
  1. 3.1 Global HPV Therapeutic Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global HPV Therapeutic Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global HPV Therapeutic Vaccines Company Ranking (2024-2026)
  4. 3.4 Global HPV Therapeutic Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global HPV Therapeutic Vaccines Company Product Type and Application
  6. 3.6 Global HPV Therapeutic Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global HPV Therapeutic Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 HPV Therapeutic Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 HPV Therapeutic Vaccines Market by Type
  1. 4.1 HPV Therapeutic Vaccines Type Introduction
  2. 4.1.1 Bivalent HPV vaccine
  3. 4.1.2 Quadrivalent HPV vaccine
  4. 4.2 Global HPV Therapeutic Vaccines Sales Value by Type
  5. 4.2.1 Global HPV Therapeutic Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global HPV Therapeutic Vaccines Sales Value by Type (2021-2032)
  7. 4.2.3 Global HPV Therapeutic Vaccines Sales Value Share by Type (2021-2032)
5 HPV Therapeutic Vaccines Market by Application
  1. 5.1 HPV Therapeutic Vaccines Application Introduction
  2. 5.1.1 Man
  3. 5.1.2 Woman
  4. 5.2 Global HPV Therapeutic Vaccines Sales Value by Application
  5. 5.2.1 Global HPV Therapeutic Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global HPV Therapeutic Vaccines Sales Value by Application (2021-2032)
  7. 5.2.3 Global HPV Therapeutic Vaccines Sales Value Share by Application (2021-2032)
6 HPV Therapeutic Vaccines Regional Value Analysis
  1. 6.1 Global HPV Therapeutic Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HPV Therapeutic Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global HPV Therapeutic Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global HPV Therapeutic Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HPV Therapeutic Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America HPV Therapeutic Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe HPV Therapeutic Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe HPV Therapeutic Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific HPV Therapeutic Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific HPV Therapeutic Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America HPV Therapeutic Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America HPV Therapeutic Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa HPV Therapeutic Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa HPV Therapeutic Vaccines Sales Value Share by Country, 2025 VS 2032
7 HPV Therapeutic Vaccines Country-level Value Analysis
  1. 7.1 Global HPV Therapeutic Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HPV Therapeutic Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global HPV Therapeutic Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global HPV Therapeutic Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt HPV Therapeutic Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt HPV Therapeutic Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt HPV Therapeutic Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Bovax Biotechnology Co., Ltd.
  2. 8.1.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
  3. 8.1.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
  4. 8.1.3 Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Product Portfolio
  6. 8.1.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
  7. 8.2 Sanofi Pasteur
  8. 8.2.1 Sanofi Pasteur Company Information
  9. 8.2.2 Sanofi Pasteur Business Overview
  10. 8.2.3 Sanofi Pasteur HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Pasteur HPV Therapeutic Vaccines Product Portfolio
  12. 8.2.5 Sanofi Pasteur Recent Developments
  13. 8.3 Johnson and Johnson.
  14. 8.3.1 Johnson and Johnson. Company Information
  15. 8.3.2 Johnson and Johnson. Business Overview
  16. 8.3.3 Johnson and Johnson. HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson. HPV Therapeutic Vaccines Product Portfolio
  18. 8.3.5 Johnson and Johnson. Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer HPV Therapeutic Vaccines Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline plc
  26. 8.5.1 GlaxoSmithKline plc Company Information
  27. 8.5.2 GlaxoSmithKline plc Business Overview
  28. 8.5.3 GlaxoSmithKline plc HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc HPV Therapeutic Vaccines Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc Recent Developments
  31. 8.6 Wantai BioPharm
  32. 8.6.1 Wantai BioPharm Company Information
  33. 8.6.2 Wantai BioPharm Business Overview
  34. 8.6.3 Wantai BioPharm HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Wantai BioPharm HPV Therapeutic Vaccines Product Portfolio
  36. 8.6.5 Wantai BioPharm Recent Developments
  37. 8.7 Serum Institute
  38. 8.7.1 Serum Institute Company Information
  39. 8.7.2 Serum Institute Business Overview
  40. 8.7.3 Serum Institute HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute HPV Therapeutic Vaccines Product Portfolio
  42. 8.7.5 Serum Institute Recent Developments
  43. 8.8 Profectus BioSciences, Inc.
  44. 8.8.1 Profectus BioSciences, Inc. Company Information
  45. 8.8.2 Profectus BioSciences, Inc. Business Overview
  46. 8.8.3 Profectus BioSciences, Inc. HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Profectus BioSciences, Inc. HPV Therapeutic Vaccines Product Portfolio
  48. 8.8.5 Profectus BioSciences, Inc. Recent Developments
  49. 8.9 Merck & Co., Inc
  50. 8.9.1 Merck & Co., Inc Company Information
  51. 8.9.2 Merck & Co., Inc Business Overview
  52. 8.9.3 Merck & Co., Inc HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co., Inc HPV Therapeutic Vaccines Product Portfolio
  54. 8.9.5 Merck & Co., Inc Recent Developments
  55. 8.10 ISA Pharmaceuticals
  56. 8.10.1 ISA Pharmaceuticals Company Information
  57. 8.10.2 ISA Pharmaceuticals Business Overview
  58. 8.10.3 ISA Pharmaceuticals HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  59. 8.10.4 ISA Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio
  60. 8.10.5 ISA Pharmaceuticals Recent Developments
  61. 8.11 INOVIO Pharmaceuticals
  62. 8.11.1 INOVIO Pharmaceuticals Company Information
  63. 8.11.2 INOVIO Pharmaceuticals Business Overview
  64. 8.11.3 INOVIO Pharmaceuticals HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  65. 8.11.4 INOVIO Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio
  66. 8.11.5 INOVIO Pharmaceuticals Recent Developments
  67. 8.12 Emergent BioSolutions
  68. 8.12.1 Emergent BioSolutions Company Information
  69. 8.12.2 Emergent BioSolutions Business Overview
  70. 8.12.3 Emergent BioSolutions HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Emergent BioSolutions HPV Therapeutic Vaccines Product Portfolio
  72. 8.12.5 Emergent BioSolutions Recent Developments
  73. 8.13 Astellas Pharma
  74. 8.13.1 Astellas Pharma Company Information
  75. 8.13.2 Astellas Pharma Business Overview
  76. 8.13.3 Astellas Pharma HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Astellas Pharma HPV Therapeutic Vaccines Product Portfolio
  78. 8.13.5 Astellas Pharma Recent Developments
  79. 8.14 2A Pharma AB
  80. 8.14.1 2A Pharma AB Company Information
  81. 8.14.2 2A Pharma AB Business Overview
  82. 8.14.3 2A Pharma AB HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  83. 8.14.4 2A Pharma AB HPV Therapeutic Vaccines Product Portfolio
  84. 8.14.5 2A Pharma AB Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst